ArticleKidney international2022
Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.
Article in Kidney international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Dulaglutide Effect on Proteins Associated With CKD Progression.Kidney international reports · 2026Article
- Olink Proteomic Profiling of Vitreous Humor and Plasma From Proliferative Diabetic Retinopathy Patients Identifies a Novel Inflammatory Molecular Endotype.Investigative ophthalmology & visual science · 2026Article
- Joslin Kidney Panel of Circulating Proteins: A Tool for ESKD Risk Discrimination and Individualized Diabetic Kidney Disease Treatment.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Review
- Selection and Validation of Novel Biomarkers for ntOPN-Based Models for Diabetic Kidney Disease in Patients With Diabetes Mellitus.Journal of diabetes research · 2026Article
- A panel of plasma proteins associated with venous thromboembolism in patients with prostate cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- Urinary Complement proteome strongly linked to diabetic kidney disease progression.Nature communications · 2025Article
- MSIght: A Modular Platform for Improved Confidence in Global, Untargeted Mass Spectrometry Imaging Annotation.Journal of proteome research · 2025Article
- Insights into the molecular underpinning of type 2 diabetes complications.Human molecular genetics · 2025Review
- Distinctive blood and salivary proteomics signatures in Qatari individuals at high risk for cardiovascular disease.Scientific reports · 2025Article
- Plasma Proteomics of Diabetic Kidney Disease Among Asians With Younger-Onset Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2025Article
- Layilin: a multifunctional hyaluronan receptor in physiology and pathology.Frontiers in oncology · 2025Review
- KLK8/HGF/Met signaling pathway mediates diabetes-associated hippocampal neuroinflammation in male mice.Theranostics · 2025Article
- Microbial and proteomic signatures of type 2 diabetes in an Arab population.Journal of translational medicine · 2024Article
- Circulating proteins linked to apoptosis processes and fast development of end-stage kidney disease in diabetes.JCI insight · 2024Article
- Integrated analysis of blood DNA methylation, genetic variants, circulating proteins, microRNAs, and kidney failure in type 1 diabetes.Science translational medicine · 2024Article
- Serum high mobility group box 1 as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes.Frontiers in immunology · 2024Article
- Causal association of plasma circulating metabolites with nephritis: a Mendelian randomization study.Frontiers in nutrition · 2024Article
- Comprehensive landscape of the miRNA-regulated prognostic marker LAYN with immune infiltration and stemness in pan-cancer.Journal of cancer research and clinical oncology · 2023Article
- Proteomic profiling of longitudinal changes in kidney function among middle-aged and older men and women: the KORA S4/F4/FF4 study.BMC medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
Abstract
This study applies a large proteomics panel to search for new circulating biomarkers associated with progression to kidney failure in individuals with diabetic kidney disease. Four independent cohorts encompassing 754 individuals with type 1 and type 2 diabetes and early and late diabetic kidney disease were followed to ascertain progression to kidney failure. During ten years of follow-up, 227 of 754 individuals progressed to kidney failure. Using the SOMAscan proteomics platform, we measured baseline concentration of 1129 circulating proteins. In our previous publications, we analyzed 334 of these proteins that were members of specific candidate pathways involved in diabetic kidney disease and found 35 proteins strongly associated with risk of progression to kidney failure. Here, we examined the remaining 795 proteins using an untargeted approach. Of these remaining proteins, 11 were significantly associated with progression to kidney failure. Biological processes previously reported for these proteins were related to neuron development (DLL1, MATN2, NRX1B, KLK8, RTN4R and ROR1) and were implicated in the development of kidney fibrosis (LAYN, DLL1, MAPK11, MATN2, endostatin, and ROR1) in cellular and animal studies. Specific mechanisms that underlie involvement of these proteins in progression of diabetic kidney disease must be further investigated to assess their value as targets for kidney-protective therapies. Using multivariable LASSO regression analysis, five proteins (LAYN, ESAM, DLL1, MAPK11 and endostatin) were found independently associated with risk of progression to kidney failure. Thus, our study identified proteins that may be considered as new candidate prognostic biomarkers to predict risk of progression to kidney failure in diabetic kidney disease. Furthermore, three of these proteins (DLL1, ESAM, and MAPK11) were selected as candidate biomarkers when all SOMAscan results were evaluated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.